Company intelligence / Profile preview

Purplepictures

Ownership: Private
Development stage: Other

Overview

Positive interim Phase 2 data in PDAC with CM24 + nivolumab + chemotherapy showing potential predictive biomarker for survival benefit. NT219 completed Phase 1 dose escalation and moving into Phase 2 in head and neck cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyTri-specific antibody
Industry: Biotech

Partnerships

Bristol Myers Squibb (CM24 clinical collaboration with nivolumab)China partner for CONSENSI® historical asset

Beyond the preview

Go deeper on Purplepictures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purplepictures.

Explore the full profile